Immune system disorder
Therapeutic area
Immunology
Rare disease
No
- Definition
- A disorder resulting from an abnormality in the immune system.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Immune system disorder
- Therapeutic area
- Immunology
- immune system disorder
- disease of immune system
- disease or disorder of immune system
- disorder of immune system
- immune disease
- immune disorder
- immune dysfunction
- immune system disease or disorder
- immune system disorder
- All therapeutic areas
- Immunology
- Severity
- Severe
- MONDO ID
- MONDO:0005046
- Parent condition
- MONDO:7770006
Related records
Broader conditions (3)
- Disease
- Disease by body system or component
- Human disease
Narrower conditions (1,579)
- 2-hydroxyethyl methacrylate sensitization
- 22q11.2 deletion syndrome
- A20 haploinsufficiency
- A53 diffuse large B-cell lymphoma
- Aagenaes syndrome
- Abdominal cystic lymphangioma
- AChR+ myasthenia gravis
- Acid sphingomyelinase deficiency
- Acquired adult-onset immunodeficiency
- Acquired agranulocytosis
- Acquired epidermolysis bullosa
- Acquired hemophagocytic lymphohistiocytosis associated with malignant disease
- Acquired immunodeficiency
- Acquired polycythemia
- Acquired polycythemia vera
- Acquired secondary polycythemia
- Acquired thrombotic thrombocytopenic purpura
- Activated PI3K-delta syndrome
- Acute allergic serous otitis media
- Acute basophilic leukemia
Trials (476)
- (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
- 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
- A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
- A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.
- A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants
- A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
- A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
- A Double-blind Randomized Controlled Trial of a Thickened Amino-acid-based Formula in Children Allergic to Cow's Milk and to Protein Hydrolysates
- A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
- A First-in-Human Phase I Trial of OX118 in Healthy Volunteers
- A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
- A Phase I Extension Trial of Repeated Infusions of ISF35
- A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
- A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
- A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
- A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
Approved drugs (47)
- Abatacept
- Adalimumab
- Alefacept
- Amifampridine phosphate
- Anakinra
- Apremilast
- Azathioprine
- Basiliximab
- Belatacept
- Belumosudil
- Bimekizumab
- Brodalumab
- Canakinumab
- Certolizumab pegol
- Cladribine
- Cyclosporine
- Daclizumab
- Darvadstrocel
- Dimethyl fumarate
- Diroximel fumarate
Drugs in development (63)
- Abetimus Phase 2
- Acetaminophen Phase 1
- Afelimomab Phase 2
- Alemtuzumab Phase 2
- Amlitelimab Phase 1
- Anisperimus Phase 2
- Antilymphocyte immunoglobulin (horse) Phase 2
- Azithromycin Phase 1
- Belantamab Phase 1
- Brepocitinib Phase 1
- Brepocitinib tosylate Phase 1
- Briakinumab Phase 3
- Busulfan Phase 2
- Cyclophosphamide Phase 2
- Daratumumab Phase 1
- Deucravacitinib Phase 1
- Dexamethasone Phase 2
- Diphenhydramine Phase 1
- Disermolide Phase 1
- Eculizumab Phase 2
Other linked drugs (11)
- Actarit
- Amifampridine
- Bucillamine
- CDP-484
- Gusperimus trihydrochloride
- Hydroxychloroquine
- Meropenem
- Napirimus
- Pegademase bovine
- Thymopentin
- Varicella zoster virus, live attenuated